Latest Conference Articles

Amonafide Plus Cytarabine Fails To Meet Primary Endpoint

Amonafide+Cytarabine may not be effective for secondary acute myeloid leukemia, according to ACCEDE trial data

High-Dose Methotrexate Better for ALL

High doses of methotrexate increases EFS for children and young adults

Molecular Profiling Boosts Targeted Therapies in Phase I Trial

Matching patients with targeted therapies based on molecular profile results in superior clinical outcomes

Dr. Joensuu on the Imatinib for High-Risk GIST Trial

Dr. Heikki Joensuu from the Helsinki University Central Hospital Summarizes the Imatinib for High-Risk high-risk gastrointestinal stromal tumors (GIST) Trial

Tim Turnham Discusses Melanoma Treatment Advances

Tim Turnham the Executive Director of the Melanoma Research Foundation Discusses Melanoma Treatment Advances

Investors Taking Stock of Key ASCO Abstracts

Oncology specialists, biopharmaceutical analysts and investors all await the latest research news from the upcoming ASCO annual meeting

Genetic Analysis Yields Biomarker for Neuropathy

A genetic analysis resulted in the discovery of the first predictive biomarker for taxane-induced peripheral neuropathy

Cabozantinib (XL184) Demonstrates Antitumor Activity and Reduces or Eliminates Bone Metastases in Multiple Cancers

Cabozantinib (XL184), an investigational oral tyrosine kinase inhibitor, demonstrated antitumor activity in multiple types of advanced solid tumors.

Study Results Show Ovarian Cancer Deaths Are Not Reduced by Early-Detection Screening Methods

The risk of dying from ovarian cancer was not reduced when women received CA-125 blood testing and transvaginal ultrasound

Study Confirms Extending Testing to Every 3 Years in Women Who Test Negative for the HPV Virus

A large-scale study of HPV testing and Pap smear for cervical cancer screening confirms that women can safely extend screening intervals from 1 to 3 years.

PSA Found to Be Highly Predictive of Long-Term Risk of Death From Prostate Cancer

Prostate-specific antigen (PSA) levels can accurately predict the risk of developing metastasis or death from prostate cancer up to 30 years later

Among Women at High Risk for Breast Cancer, Study Finds Smoking, Not Moderate Alcohol Use, Increases Risk of Common Cancers

A prospective study analyzed the risk of contracting common cancers based on baseline self-reporting data on smoking, alcohol use, and physical activity

Stay tuned for Live Conference Coverage from ASCO 2011

ASCO 2011, June 3-7, 2011 McCormick Place, Chicago, IL

Donna Berry on Winning Researcher Award

Donna Berry on the Distinguished Researcher Award and Her Advice to Researchers

ONS President Carl Brown on Key Messages of the Congress

Carlton Brown Describes Key Messages of the ONS Congress

Cancer Survivor Charlie Lustman Lives to Tell His Story

Keynote Presenter Cancer Survivor Charlie Lustman Lives to Tell His Story

Susan Moore on Adapting a Practice for Oral Oncolytics

Susan Moore Oncology Nurse Practitioner/Consultant, MCG Oncology on Adapting a Practice for Use of Oral Oncolytics

Addressing the Challenges of Oral Oncolytic Therapy

Oral oncolytics are frequently used in cancer treatment and they make up approximately 25% of the medications in the oncology pipeline

Cure Magazine Presents Extraordinary Healer Award

Honorary Mistress of Ceremonies Cynthia Nixon kicked off the ONS 36th Annual Congress Cure magazine Extraordinary Healer Award with a rousing tribute

What Nurses May Not Know About Lymphedema

Lymphedema is the treatment-induced buildup of extra lymph fluid in tissues that causes discomforting and potentially debilitating swelling of the limbs

Provenge Treatment Requires Multidisciplinary Care Coordination

At ONS researchers from the Seattle Cancer Care Alliance (SCCA) discussed their multidisciplinary care coordination approach for treating patients with Provenge

Oncology Nurses Explore the Social Media Scene

Social media programs allow oncology nurses to network, share information, and learn evidence-based practices

Ipilimumab's Unique Side Effects Require Unique Management

The FDA recently approved the immunotherapy ipilimumab (Yervoy) as a second-line treatment for patients with metastatic melanoma

Elizabeth Blasiak Discusses the ONS Congress

Elizabeth Blasiak on the Significance of the ONS Congress

Changing Paradigms-Integrating Novel Therapeutics Into the Standard of Care

Prostate cancer affects 1 of every 6 men in the United States

Considerations for Integrating Chemotherapy

Traditional, linear regimen of prostate cancer treatment may need to be reexamined as oncologists learn new ways to incorporate new therapies

Bone-Targeted Therapeutics

Initial clinical findings indicate that results with radiotherapies sometime improve when combined with immunotherapy

Immunotherapies: Avoiding collisions once the brake is released

Immunotherapies again made headlines in oncology last month

Novel Hormone-Radiation Therapy Approaches

Radiation therapy (RT) used in combination with hormonal approaches continues to be a viable strategy for treating localized high-risk prostate cancer patients

PSA: To Screen or Not to Screen

Screening for prostate cancer does work, despite controversy about its efficacy, according to IPCC Co-chair Leonard G. Gomella